23andMe has turned customers’ data into a cancer drug
GlaxoSmithKline is developing a novel cancer drug that doubles as the first treatment to be validated using 23andMe’s genetic database, culled from its more than 12 million customers.
As STAT’s Matthew Herper reports, the drug is an antibody treatment targeting the CD96 receptor and meant to help the immune system attack cancer cells. It just entered Phase 1 clinical development.
The drug is a product of the two-year-old deal between the two companies and represents “a major milestone” for 23andMe, CEO Anne Wojcicki said. There are now 30 research projects underway in the collaboration, up from just eight when the companies first aligned.
Read more.
As STAT’s Matthew Herper reports, the drug is an antibody treatment targeting the CD96 receptor and meant to help the immune system attack cancer cells. It just entered Phase 1 clinical development.
The drug is a product of the two-year-old deal between the two companies and represents “a major milestone” for 23andMe, CEO Anne Wojcicki said. There are now 30 research projects underway in the collaboration, up from just eight when the companies first aligned.
Read more.
No hay comentarios:
Publicar un comentario